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Abstract: 
 
Background: Reductions in blood pressure are common during the treatment of acute 
decompensated heart failure (ADHF) and strongly associated with worsening renal 
function (WRF). However, it is unclear whether a decline in systolic blood pressure 
(SBP), and the associated deterioration in renal function, might limit successful diuresis. 
Methods: We analyzed consecutive admissions with a primary discharge diagnosis of 
ADHF (n=657).  Metrics of diuresis were assessed for their association with a decline in 
SBP from admission to discharge in addition to the use or titration of guideline 
recommended heart failure therapies (GDMT). SBP-reduction was defined as a relative 
reduction in SBP greater than the median value (>9.9%). 
Results: Overall 77.6% of the population had a discharge SBP lower than the admission 
value. SBP-reduction resulted in significantly higher rates of WRF (OR= 1.9, p=0.004). 
Despite the negative impact on renal function, SBP-reduction was not associated with 
worse diuretic efficiency (p=0.274). Furthermore, the rate of hemoconcentration, net fluid 
loss, weight loss, adjuvant thiazide diuretic use, and loop diuretic infusion use was not 
different for patients with an SBP-reduction (p≤0.293for all). GDMT such as ACE-Is and 
beta blockers were associated with SBP-reduction but not with metrics of decongestion. 
Conclusion: Despite apparent negative effects on renal function, a reduction in blood 
pressure or titration of GDMT did not appear to limit successful decongestion. 
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Introduction: 
Acute decompensated heart failure (ADHF) is a serious problem affecting over 
1,000,000 Americans annually and is the most common hospital discharge diagnosis 
among Medicare beneficiaries.1 A diagnosis of ADHF carries with it a poor prognosis 
with a one-year post-discharge mortality of 33%.2-4 Six month readmission rates stand 
near 50%, reflecting the challenging problem of effectively managing ADHF.5 The 
economic burden associated with ADHF is substantial and accounts for more than half of 
all heart failure expenditures.6 To date, ADHF research has enjoyed limited success aside 
from the description of the poor survival associated with this condition.7 
Underlying the challenge in treating ADHF are the complex pathophysiologic 
mechanisms involved in its genesis. On a fundamental level, ADHF is predominantly a 
disease of congestion and volume overload.8,9 Patients suffering from ADHF often 
present with signs of excess volume such as peripheral edema, jugular venous distention, 
and dyspnea. Consequently, returning patients to a euvolemic state remains the primary 
treatment goal and one of the strongest predictors of survival in patients with heart 
failure. 10,11 The presence of volume overload likely plays a pathologic role and directly 
contributes to heart failure disease progression.12 Venous congestion leads to increased 
sympathetic activity and activation of the renin-angiotensin-aldosterone system (RAAS), 
both of which increase cardiac strain and induce pathologic remodeling of the 
myocardium.13 From a clinical standpoint, neurohormonal activation leads to progression 
of heart failure and worse outcomes.14 Taking all of this information into consideration, 
finding effective treatments paradigms to remove volume in ADHF has been a top 
priority.  
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Loop diuretics have a longstanding utility in ADHF and remain the mainstay of 
therapy in congestive heart failure.15 While treatment with loop-diuretics proves to be 
effective, there are limitations and drawbacks to its intensive and prolonged use.16 Loop-
diuretics inherently function to induce volume loss through natriuresis. One early-
identified phenomenon was that repeated dosing results in reduced natriuresis and 
efficacy of the subsequent dose. This occurs on a dose-to-dose basis in a phenomenon 
known as diuretic braking.17 It also occurs on a long-term, progressive basis which is 
termed diuretic resistance.18 Both of these issues arise from renal compensation stemming 
from exposure to loop-diuretics. Increased sodium delivery to the tubule with diuretic 
therapy results in tubular hypertrophy, increased sodium absorption, and decreased 
diuretic responsiveness.18,19 Furthermore, neurohormonal activation in response to 
diuretic therapy supports the tubular and vascular compensatory mechanisms that result 
in increased sodium avidity by the kidney and decreased diuretic responsiveness. To 
reach the important goal of decongestion, the dose of loop-diuretics is increased to 
overcome resistance. However, increased doses of loop-diuretics are linked to 
neurohormonal activation, and poorer outcomes.20,21 Consequently, new heart failure 
treatment strategies must consider maintaining responsiveness to loop-diuretics while 
aiming to effectively remove excess fluid.  
Guideline directed medical therapies (GDMT) temper the negative effects of 
neurohormonal activation that is the consequence of both ADHF physiology and diuretic 
therapy. Accordingly, initiating and increasing the dosages of these medications is 
another important goal recommended by heart failure guidelines to reduce mortality and 
disease progression.22-24 The primary GDMTs include angiotensin converting enzyme 
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inhibitors (ACE-Is), Angiotensin II receptor blockers (ARBs), beta-blockers, and 
mineralocorticoid receptor antagonists (MRAs). Inhibition of the renin-angiotensin-
aldosterone-system with ACE-Is reduces mortality, and this effect has been repeatedly 
proven in large clinical trials.25-27 For patients who cannot tolerate ACE-Is, ARBs can be 
utilized as several large studies validated that they are comparable in efficacy.28,29 Both of 
these medicines work to reduce mortality in heart failure by several mechanisms, many of 
which are still in the process of being studied. One readily observed action of ACE-
Is/ARBs is to lower blood pressure, counteracting the vasoconstrictive effects and 
increased sodium reabsorption resulting from RAAS activation. RAAS mediated cardiac 
fibroblast proliferation and cardiomyocyte apoptosis that cause ventricular remodeling 
are also likely reduced both by lowering blood pressure and by the direct action of these 
medications on cardiac tissue.30,31 However, side effects of these medications include 
cough (with ACE-Is), hyperkalemia, and a decrease in GFR. Beta-blockers are another 
important pillar of heart failure therapy. They are a longstanding component of therapy, 
and their use in heart failure is supported by multiple, large studies in the literature.32-34 
These medications work by inhibiting different elements of beta-adrenergic activation, 
reducing cardiac strain and oxygen consumption by lowering heart rate and cardiac 
contractility.34 Finally, spironolactone and eplerenone are MRAs that function by 
displacing aldosterone from the mineralocorticoid receptor in the collecting duct of the 
nephron. Eplerenone additionally has been shown to reduce the aldosterone-mediated 
cardiac remodeling, demonstrating the advantages drawn from the direct effect of these 
medications on cardiac tissues.35 As such, their use is recommended by guidelines 
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following major trials that demonstrated a survival benefit with the use of MRAs in heart 
failure.36-38 
One consideration with the use of GDMT is the reduction of blood pressure 
caused by these therapies. The systolic blood pressure (SBP) decreases in response to 
ADHF therapy through combinations of the direct vascular effects of the medications, 
reduced cardiac contractility, and volume reduction. In some ways, this is a desirable 
outcome, and chronic therapies are tailored to reduce longstanding elevations in blood 
pressure. Hypertension is a common co-morbidity in heart failure, and on a chronic basis 
is associated with adverse cardiovascular morbidity and mortality. Accordingly, society 
guidelines recommend lowering blood pressure to improve cardiovascular outcomes and 
survival.22 However, short-term reductions in blood pressure during hospitalization for 
ADHF may be antagonistic to the primary acute goals of ADHF therapies.  
An emerging signal is that a decline in blood pressure during hospitalization 
strongly links to worsening renal function (WRF) during the treatment of ADHF. 39-42 
WRF is an adverse outcome in heart failure, and is often defined in the literature as either 
a >20% decrease in GFR or a creatinine increase of 0.3 mg/dL.43 Initial studies of WRF 
discovered that WRF was both a common feature in heart failure, and associated with a 
worse prognosis.44 Relatedly, cardiorenal syndrome develops frequently in patients with 
heart failure. Cardiorenal syndrome is defined by a decrease in kidney function 
associated with heart failure. This loose definition incorporates kidney disease leading to 
cardiovascular disease, acute kidney injury in response to hear failure, and primarily, 
compromise of kidney function secondary to congestive heart failure.45 Originally, 
decreases in cardiac output and blood pressure secondary to the hemodynamic 
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derangements of heart failure were thought to decrease renal perfusion and lead to 
damage. However, venous congestion has proven to more closely correlate with WRF 
while parameters of cardiac output poorly associate with WRF.46,47 This new paradigm 
links the unfavorable prognosis seen with congestion, neurohormonal activation, and 
WRF. As our understanding of the cardiorenal syndrome grows, new opportunities are 
realized for improving ADHF outcomes. 
It has become apparent that the cause of WRF is of more prognostic relevance 
than WRF itself.43 Notably, WRF associated with SBP-reduction proved to be a 
phenotype not linked to worse prognosis, thus demonstrating the need for a better 
understanding of the relationship between blood pressure and WRF during ADHF.42 
Normally, maintenance of GFR across a wide range of blood pressures occurs primarily 
through renal autoregulation at the level of the glomerulus. The two primary mechanisms 
employed by the kidney to maintain GFR are tubuloglomelular feedback (TGF) and 
myogenic feedback. Both of these mechanisms ensure protection of the delicate 
glomerulus during periods of elevated blood pressure and maintenance of GFR as blood 
pressure decreases. TGF works by utilizing the macula densa to infer changes in blood 
pressure through the distal tubule flow. Nevertheless, recent data indicates that the  
myogenic response is the primary autoregulatory mechanism, especially in protecting the 
glomerulus from increases in blood pressure.48 The myogenic response acts by measuring  
perturbations in blood pressure through stretch receptors in the afferent arteriole. 
Vascular tone of the afferent arteriole is then either increased or decreased in response to 
high or low blood pressure, respectively. The predominance of the myogenic response to 
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fluctuations in blood pressure explains why GFR is predominantly pressure dependent 
rather than flow dependent.49 Moreover, it has been demonstrated that changes  
 
Figure 1: Theoretical diagram demonstrating the maintenance of GFR over a wide 
range of blood pressure by the process of renal autoregulation. 
 
in systolic blood pressure, rather than diastolic blood pressure, is the primary stimulus for 
the myogenic autoregualtion. 48 
Despite the robust autoregulation seen in normal subjects, the GFR of ADHF 
patients is linked closely with changes in blood pressure. Congestive heart failure 
presents a unique environment in which the mechanisms for autoregulation are 
impaired.50 Often this is attributable to damage of the regulatory mechanisms that occur 
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with common co-morbidities of heart failure. Longstanding hypertension leads to 
pathologic remodeling of the afferent arteriole which subsequently damages the ability to 
autoregulate.51 Furthermore, the presence of diabetes can lead to alterations in both the 
vascular and possibly tubular components of renal autoregulation.52 
 
Figure 2: Risk of WRF correlates to change in SBP in heart failure patients. Adopted 
form Dupont, Eur. J. Heart Failure, 2013 
 
When examining the components of ADHF therapy, and their physiologic 
manifestations, the question arises whether they can ever be counterproductive. Many of 
the therapies currently employed in ADHF result in a reduction in blood pressure. 
Guidelines recommend using hospitalization for ADHF as an opportunity to optimize or 
initiate chronic oral medications such as beta-blockers, ace-inhibitors, and vasodilators, 
leading to the opportunity for further iatrogenic reduction in blood pressure. 23,24,53 Given 
that a reduction in blood pressure during the treatment of ADHF is strongly associated 
with WRF, and considering the kidney is the primary conduit by which volume is 
removed, it is unclear if elective titration of vasodilators and neurohormonal antagonists 
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may be contrary to the immediate goal of fluid removal in ADHF. Society guidelines do 
not address how, or if, these goals can be achieved simultaneously due to the paucity of 
evidence on the subject in the current literature. 
Statement of Purpose:  
To date, there is little research outlining the effect that initiating or increasing GDMT has 
on diuretic therapy during ADHF hospitalization. An important element to this puzzle is 
whether changes in systolic blood pressure impact diuresis with loop-diuretics. Especially 
when considering the failure of renal autoregulatory mechanisms in ADHF and the high 
rates of WRF as blood pressure decreases. Despite these challenges, further research is 
necessary to allow for evidence-based decision making for clinicians treating heart failure 
patients. This study acts as a first step in directly addressing this issue.   
Aim 1: Determine whether a decrease in blood pressure from admission to discharge will 
affect decongestion as assessed by diuretic efficiency  
Hypothesis 1:  SBP-reduction, defined as a greater than median decrease in SBP from 
admission to discharge, will not reduce diuretic efficiency 
Aim 2: Investigate the effect of initiating or titrating guideline recommended medications 
during hospitalization on blood pressure, renal function, and decongestion. 
Hypothesis 2: GDMTs will increase rates of blood-pressure reduction and WRF, but will 
not affect diuretic efficiency. 
 
 
 
Methods: 
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Cohort:  
The study population was drawn from consecutive admissions to the Hospital of the 
University of Pennsylvania cardiology and internal medicine services between 2004 and 
2009. Inclusion required a B-type natriuretic peptide (BNP) level of > 100pg/mL within 
24 hours of admission, receipt of intravenous loop diuretics, and availability of data on 
fluid intake and output during the hospitalization. Patients selected had a length of stay 
between 2 and 14 days (excluding patients who underwent limited or 
extensive/complicated decongestion). Patients requiring renal replacement therapy were 
excluded. In the event of multiple hospitalizations for a single patient, only the first 
admission that satisfied the inclusion and exclusion criteria was used. Overall, a total of 
657 were included in the cohort. The Social Security Death Index was used to determine 
all-cause mortality. Patient status was determined 2.5 years after discharge of the last 
patient in the data set.54 
Variable Definitions: 
The admission SBP was calculated as the average of the first 3 recorded values in 
the chart and discharge SBP from the last three.  The relative (%) change in SBP was 
calculated by dividing the absolute SBP change by the calculated admission SBP. 
Glomerular Filtration Rate (GFR) was calculated using the four variable Modification in 
Diet for Renal Disease (MDRD) formula. WRF was defined as ≥ 20% decrease in GFR. 
This previously utilized definition accounts for the non-linear relationship between renal 
function and serum creatinine.43,55 Conversely, improvement in renal function (IRF) was  
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Figure 3: Consort Diagram 
 
defined as a ≥20% increase in GFR. Comparisons in GFR were from admission to 
discharge unless otherwise stated. The average daily net fluid balance is the total net 
input/output divided by the length of stay (LOS). Hemoconcentration was defined as an 
increase in both hemoglobin (hgb) and hematocrit (hct) at discharge as compared to 
admission values consistant with our prior description of hemoconcentration in this 
populaiton.56 
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Loop diuretic doses were converted to furosemide equivalents with 1mg 
bumetanide = 20 mg torsemide = 80 mg furosemide for oral doses, and 1mg bumetanide 
= 20 torsemide = 40 furosemide for intravenous doses.57,58 The total loop diuretic given 
during hospitalization is the sum of the total oral and IV loop diuretics given from 
admission to discharge. Diuretic efficiency (DE) was calculated by dividing the total net 
output during hospitalization by total IV loop-diuretic dose (40mg IV furosemide 
equivalents) during hospitalization.59 High diuretic efficiency was defined as values 
above the median. For medication analysis, angiotensin converting enzyme inhibitors 
(ACE-Is) were converted to lisinopril equivalents and Angiotensin II receptor blockers 
(ARBs) were converted to losartan equivalents for comparison.  
Statistical analysis: 
 Values are reported as Mean ± standard deviation or median with interquartile 
range for continuous variables, and proportion (%) for discrete variables. Student t test or 
Wilcoxon rank-sum test was used to compare continuous variables between 2 groups of 
patients. The independent-Samples Kruskal-Wallis Test was used to compare values 
across the quintiles of relative decline in SBP. Proportions for baseline variable and study 
analysis were examined using the χ2test. Odds-ratio, 95% confidence intervals, and p-
values for the comparison of two nominal variables were computed using binary logistic 
regression. 
 The independent association between blood-pressure and medication variables 
associated with DE was determined using logistic regression. Baseline variables with a 
univariate association with DE at p<0.2 were entered into this model to adjust for 
potential confounding variables. These included age, sex, hematocrit, hemoglobin, BNP, 
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creatinine, and sodium, eGFR, ejection fraction, hypertension, diabetes, ace-inhibitor or 
ARB, beta-blocker, thiazides, and hydralazine. 
 Cox proportional hazards modeling was used to evaluate time-to event 
associations with all-cause mortality. Candidate covariates entered into the model were 
relevant baseline characteristics with less than 10% missing values and a univariate 
association with mortality at p<0.2. These variables included: age, race, diabetes mellitus, 
ischemic HF cause, presence of edema, digoxin use, outpatient loop diuretic dose, 
thiazide diuretic use, heart rate, systolic blood pressure, B-type natriuretic peptide, serum 
sodium, hemoglobin, GFR, and blood urea nitrogen. Other covariates with a theoretical 
potential for confounding but a univariate association with mortality at p>0.2 were forced 
into the model. Models were built using backward elimination such that covariates with 
an association with mortality at p<0.2 were retained.60 P-values<0.05 were considered 
significant. Statistical analysis was performed with IBM SPSS Statistics version 21.0 
(IBM Corp, Armonk, NY). 
SPSS Coding: 
Calculated variables and examples provided for each statistical analysis used: 
 
eGFR: 
compute AdmitUnadjustedGFR= 175*(AdmitCreat**-1.154)*(AGE**-0.203). 
if RACE eq 2 and sex eq 2 GFRadmit=AdmitUnadjustedGFR*1.212*0.742. 
if RACE eq 2 and sex eq 1 GFRadmit=AdmitUnadjustedGFR*1.212. 
if RACE ne 2 and sex eq 2 GFRadmit=AdmitUnadjustedGFR*0.742. 
if RACE ne 2 and sex eq 1 GFRadmit=AdmitUnadjustedGFR. 
 
 
Patients Taking 2 of 3 GDMT (same or increased dosage): 
compute GDMT2of3=0. 
if ACE_ARB_sameORincr=1 and BB_sameORincr=1 GDMT2of3=1. 
if ACE_ARB_sameOrincr=1 and Spiro_given_IH=1 GDMT2of3=1. 
if BB_sameORincr=1 and SPiro_given_IH=1 GDMT2of3=1. 
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Patients Taking 2 of 3 GDMT (increased dosage only): 
compute GDMTincr2of3=0. 
if ACE_ARB_incr=1 and BB_increase=1 GDMTincr2of3=1. 
if ACE_ARB_incr=1 and Spiro_newstart=1 GDMTincr2of3=1. 
if BB_increase=1 and SPiro_newstart=1 GDMTincr2of3=1. 
 
Determining the frequencies, mean, median, standard deviation, and interquartile range 
for study variables: 
FREQUENCIES VARIABLES=deltaSBPavg deltaSBPavg_per 
  /NTILES=4 
  /STATISTICS=STDDEV MEAN MEDIAN 
  /ORDER=ANALYSIS. 
 
Chi-square: 
CROSSTABS 
  /TABLES=deltaSBPavg_perMedian BY WRF20GFR_AD 
  /FORMAT=AVALUE TABLES 
  /STATISTICS=CHISQ RISK  
  /CELLS=COUNT ROW COLUMN  
  /COUNT ROUND CELL. 
 
 
Unadjusted Binary Logistic Regression: 
LOGISTIC REGRESSION VARIABLES mgperMLmedianAK 
  /METHOD=ENTER deltaSBPavg_perMedian  
  /PRINT=CI(95) 
  /CRITERIA=PIN(0.05) POUT(0.10) ITERATE(20) CUT(0.5). 
 
 
Adjusted Binary Logistic Regression (dependent variable, independent variable of 
interest, relevant baseline variables for adjustment): 
LOGISTIC REGRESSION VARIABLES mgperMLmedianAK 
  /METHOD=ENTER deltaSBPavg_perMedian Loop_B Age Sex AdmitCreat 
admitBUN admitHct AdmitHGB AdmitNA BNP EF HTN DM  
    ACEorARB_B BaselineBB Thiazide_B hydralazine_B GFRadmit 
  /Print=CI(95) 
  /CRITERIA=PIN(.05) POUT(.10) ITERATE(20) CUT(.5). 
 
 
Student t test: 
T-TEST GROUPS=deltaSBPavg_perMedian(0 1) 
  /MISSING=ANALYSIS 
  /VARIABLES=LOS 
  /CRITERIA=CI(.95). 
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Wilcoxon rank sum test: 
NPTESTS  
  /INDEPENDENT TEST (mlPERMG) GROUP (deltaSBPavg_perMedian)  
  /MISSING SCOPE=ANALYSIS USERMISSING=EXCLUDE 
  /CRITERIA ALPHA=0.05  CILEVEL=95. 
 
Independent-Samples Kruskal-Wallis Test: 
NPTESTS  
  /INDEPENDENT TEST (mlPERMG) GROUP (deltaSBPavg_per_quint)  
  /MISSING SCOPE=ANALYSIS USERMISSING=EXCLUDE 
  /CRITERIA ALPHA=0.05  CILEVEL=95. 
 
 
Unadjusted Cox-Regression Model: 
COXREG TimeinStudy_6_14_12 
  /STATUS=Death_YN_6_14_12(1) 
  /METHOD=ENTER deltaSBPavg_perMedian  
  /PRINT=CI(95) 
  /CRITERIA=PIN(.05) POUT(.10) ITERATE(20). 
 
 
Adjusted Cox-Regression Model: 
COXREG TimeinStudy_6_14_12 
  /STATUS=Death_YN_6_14_12(1) 
  /METHOD=ENTER deltasbpavg_permedian Age HR SBPavg  loop_B  AdmitNA   
AdmitHGB BNP GFRadmit admitBUN Race DM ischemicEtiology EdemaQuart  
Digoxin_B Thiazide_B ThiazideDis IH_ACE_ARB_yn LoopDis  DigoxinDis SpiroDis 
BBdis LOS milrinone dobutamine   EdemaDisQuart   AdjuvantThiazide  
HemoconcentrateBOTHdis   WRF20GFR_AP 
  /PRINT=CI(95) 
  /CRITERIA=PIN(.05) POUT(.20) ITERATE(20). 
 
 
Project Responsibilities: 
 The student (Kula) was responsible for the majority of the activities related to this 
investigation. The student defined and calculated all medication variables, with final 
approval by the mentor. The student completed all statistical analysis relating to SBP-
reduction in relation to WRF, DE, other diuretic metrics, and survival; as well as all 
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statistical analysis relating to medications. Additionally, the student designed all figures 
(non-cited), graphs, and charts in this publication.  The mentor (Testani) was responsible 
for providing the database previously collected by his research team, deciding on the 
definition of SBP-reduction, guidance of the relevance and direction of analysis, and 
approving all figures, charts, and graphs. Additional contributions and discussions were 
utilized from the other individuals listed in the ‘acknowledgements’ section of this work.  
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Results: 
Baseline variables and change in blood pressure: 
Baseline characteristics for the cohort are presented in Table 1.  Overall, 77.6% 
of patients had a discharge SBP lower than the admission value, which translated into a 
median absolute SBP-reduction of 12.3 mmHg (IQR -25.3 to -1.7). The median relative 
reduction in SBP was 9.9% (IQR 18.2 to 1.4). Patients with SBP-reduction on average 
had higher baseline SBP, HR, and a lower EF.  Notably, baseline medications were 
similar across all groups with the exception of the loop diuretic dose, which tended to be 
lower in the SBP-reduction group (Table 1).  
Relationship between SBP reduction, renal function, and diuresis 
 Similar to previous observations, SBP-reduction was associated with WRF (OR 
1.9, 95% CI: 1.2-2.9, p=0.004) and negatively associated with improvement in renal 
function (IRF) (OR 0.43, 95% CI: 0.28-0.65, p<0.0001). Relatedly, the risk of worsening 
vs. an improvement was substantially more likely in patients with SBP-reduction (OR 
3.4, 95% CI:  2.0-6.0, p<0.0001).   
Despite the association with deteriorations in renal function, SBP-reduction did 
not appear to limit decongestion (Table 2). Importantly, diuretic efficiency did not differ 
between those with and without SBP-reduction [523mL output/40mg IV furosemide eq 
(IQR 194-1086) vs. 429mL output/40mg IV furosemide eq (IQR 192-977); p=0.300]. 
Patients with an SBP-reduction were no more likely to have high diuretic efficiency (OR 
for above median DE: 1.2, 95% CI: 0.87-1.61, p=0.274) (Figure 4), and this held true in 
the multivariate model (OR SBP-reduction: 1.08, 95% CI: 0.8-1.5, p=0.720). SBP-
reduction,  
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Table 1: Baseline characteristics for study population 
 
Overall 
(n=657) 
SBP reduction greater 
than median (n=328) 
SBP reduction less 
than median (n=328) p-value 
Demographics     
Age (years) 62.8 ±15.4 62.4 ±15.0 63.2 ±15.9 0.542 
Male 0.565 0.521 0.607 0.27 
African American 65% 71% 58% <0.0001* 
Medical History     
Hypertension 73% 75% 71% 0.333 
Diabetes mellitus 42% 38% 46% 0.040* 
Ischemic cause 26% 22% 29% 0.040* 
EF ≥40% 32% 30% 35% 0.113 
Admission physical 
examination     
Heart rate, bpm 89.4 ±20.0 91.0 ±19.4 87.8 ±20.5 0.037* 
SBP, mmhg 131.6 ±28.9 142.3 ±29.7 120.8 ±23.8 <0.0001* 
DBP, mmhg 77.1 ±18.4 83.9 ±18.4 70.3 ±15.6 <0.0001* 
JVD (≥12 cm 
water) 61% 64% 58% 0.131 
Hepatojugular 
reflex 23% 23% 22% 0.824 
Edema (≥1) 46% 42% 51% 0.034* 
Cardiac function     
EF, % 32.1 ±20.2 30.4 ±19.6 33.8 ±20.7 0.031* 
Laboratory values     
Creatinine, mg/dl 1.6 ±0.87 1.46 ±0.85 1.66 ±0.88 0.002* 
BUN, mg/dL 30.28 ±22.6 26.3 ±18.4 34.3 ±25.7 <0.0001* 
Hematocrit 36.4  ±6.3 37.1 ±6.0 35.7 ±6.6 0.007* 
Hemoglobin, g/dL 12.1 ±2.1 12.3 ±2.0 11.9 ±2.2 0.018* 
BNP, pg/mL 1693 ±1193 1700 ±1149 1687 ±1238 0.887 
Sodium, mmol/L 138 ±4.7 139 ±4.4 138 ±4.9 0.002* 
eGFR, mL/min per          
1.73 m2 59±28 62±28 55±28 0.001* 
Medications 
(admission)     
ACE inhibitor or 
ARB 64% 65% 62% 0.464 
Beta blocker 71% 71% 72% 0.665 
Thiazide 13% 14% 11% 0.196 
Digoxide 26% 25% 26% 0.655 
Hydralazine 12% 14% 10% 0.095 
Nitrates 17% 17% 16% 0.600 
Daily Loop-         
diuretic dose, mg 
40 (17.5 to 
120) 40 (0 to 80) 40 (20 to 160) 0.035* 
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(Previous Page) Baseline characteristics for the overall cohort and patients with or 
without an SBP-reduction. SBP-reduction defined as relative SBP reduction from 
admission to discharge greater than the median (>9.9% reduction). Values are listed 
as mean standard deviation, median (quartile 1-quartile 4), or % of cohort. ACE= 
angiotensin converting enzyme, ARB- angiotensin receptor blocker, BUN- Blood 
Urea Nitrogen, eGFR- estimated glomerular filtration rate (MDRD), EF= ejection 
fraction, BNP=Brain Natriuretic Peptide, JVD= jugular venous distention, 
SBP=systolic blood pressure, DBP=diastolic blood pressure.  
 
when compared to patients without an SBP-reduction, did not affect other metrics of 
diuretic success such as total net urine output (5440 ±6741mL vs. 4933 ±5913mL, 
p=0.306), daily net-urine output (854 ±875mL/day vs. 781 ±903mL/day, p=0.293), 
dosages of loop-diuretics (112 ±101 mg furosemide eq/day vs. 119± 96 mg furosemide 
eq/day, p=0.387), use of adjuvant thiazides (15% vs. 16%, p=0.733), percent of loop-
diuretic given intravenously (65 ±25% vs. 65 ±25%, p=0.991) day of transition of loop-
diuretics to the oral route (4.2±2.4 days vs. 4.5±2.5 days, p=0.236), percentage of patients 
achieving hemoconcentration (31% vs. 34%, p=0.425), and length of stay (6.4±3.2 days 
vs. 6.7±3.3 days, p=0.249) (Table 2). The extent of SBP reduction did not influence 
diuretic efficiency (p=0.58 for variation across all quintiles of relative decline in SBP) 
(Figure 5).  
Further investigation examined the relationship between SBP-reduction, renal 
function, and decongestion stratified by whether the patient’s admission SBP was above 
or below the median value (now referred to as ‘higher admission SBP’ or ‘lower’ 
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Figure 4: Odds Ratio (OR) and 95% CI for patients with an SBP-reduction. High 
DE defined as DE greater than median, Low LOS defined as length of stay less than 
median, Less total loop-diuretic defined as below median usage of sum of both oral 
and IV loop-diuretic (furosemide equivalents).  IRF=improvement in renal function 
(>20% increase in eGFR from admission to discharge).  
 
 
 
 
 
 
0.1 1 10
Short length of stay
Decreased loop-diuretic use
Higher daily Net output
Hemoconcentration
High Diuretic Efficiency
IRF
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admission SBP’). The median admission SBP for the entire study population was 
127.5mmHg (IQR: 110-151mmHg).  SBP-reduction occurred in 64% and 34% of 
patients with an admission SBP above and below the median, respectively. Relatedly, the 
odds of SBP-reduction were tripled for those with a higher admission SBP (OR: 3.1, 95% 
CI: 2.3-4.3, p<0.001). There was no significant difference in the rates of WRF with SBP-
reduction for those with a lower admission SBP Table 3. However, SBP-reduction was 
associated with WRF in patients with a higher admission SBP (OR WRF: 2.3, 95% CI: 
1.2-4.3, p=0.012). Notably, diuretic efficiency was similar for all groups. SBP-reduction 
did not reduce diuretic efficiency whether it was in the context of a lower or higher 
admission SBP Table 3.  The lack of association between SBP-reduction and diuretic 
efficiency remained in regression models when adjusting for admission SBP value (OR: 
1.24, 95% CI: 0.9-1.7, p=0.209). Models including the relative decline in SBP during 
hospitalization (continuous) and admission SBP value yielded similar results (OR: 1.11 
per 10% decrease in SBP admission to discharge, 95% CI: 0.97-1.3, p=0.115). 
SBP-reduction and survival 
In a univariate model, SBP-reduction was associated with a survival advantage 
(HR: 0.79, CI: 0.6-0.97, p=0.026). However, this was no longer significant (HR:0.9, 
p=0.398) after adjusting for baseline-SBP. Furthermore, SBP-reduction had no 
association with mortality in a multivariate model including relevant baseline and in 
hospital variables which included: age, race, diabetes mellitus, ischemic HF cause, 
presence of edema, digoxin use, outpatient loop diuretic dose, thiazide diuretic use, heart 
rate, systolic blood pressure, B-type natriuretic peptide, serum sodium, hemoglobin, 
GFR, and blood urea nitrogen. (HR: 1.1, CI: 0.8-1.4, p=0.708). Figure 6 
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Table 2: SBP-reduction and metrics of diuresis  
 No SBP-reduction SBP-reduction p-value 
Diuretic Efficiency 
(mL output/40mg IV furosemide eq) 
429 (192-977) 523 (194-1086) 0.300 
Net output (mL) 4933 ±5913 5440 ±6741 0.306 
Daily Net I/O (mL/day) 781 ±903 854 ±875 0.293 
Total Loop Diuretic 
(mg furosemide eq) 
560 (280-1075) 440 (220-1035) 0.772 
Daily Loop Diuretic 
(mg furosemide eq/day) 
119± 96 112 ±101 0.387 
Peak IV Dose in 24hrs (mg) 162 ±140 149 ±148 0.226 
% of Loop given IV  65 ±25 65 ±25 0.991 
% requiring Adjuvant Thiazide 16% 15% 0.733 
Day switch to standing oral loop 
diuretic (days) 
4.52 ±2.5 4.2 ±2.4 0.236 
Hemoconcentration at Discharge 34% 31% 0.425 
WRF 12% 21% 0.003* 
LOS (days) 6.73± 3.3 6.43 ±3.2 0.249 
 
Metrics of diuretic success in patients with or without an SBP-reduction. Diuretic 
efficiency was estimated using net output during hospitalization divided by the total 
IV of loop diuretic administered during hospitalization (per 40 mg furosemide 
equivalents). WRF= worsening in renal function, LOS= length of stay * significant p 
value 
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Table 3: Diuretic Efficiency (A) and rates of WRF (B) for SBP-
reduction, stratified by median admission SBP 
A 
  
Diuretic 
Efficiency (mL 
output/40mg IV 
furosemide eq) p-value 
 
admission 
SBP below 
127.5mmHg 
SBP reduction  
 (n=118) 488 0.86 
 
 
no SBP reduction  
(n=209) 496 
 
admission 
SBP above 
127.5mmHg 
SBP reduction  
 (n=210) 541 0.055 
 
no SBP reduction  
(n=119) 388 
     B         WRF p-value 
 
admission 
SBP below 
127.5mmHg 
SBP reduction   
(n=118) 16% 0.349 
 
no SBP reduction  
(n=209) 12% 
 
admission 
SBP above 
127.5mmHg 
SBP reduction  
(n=210) 23% 0.010 
 
no SBP reduction  
(n=119) 12% 
 
*Admission SBP of 127.5mmHg equals the median value for the cohort  
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Figure 5: Median diuretic efficiency as compared quinitles of relative decline in SBP 
from admission to discharge. (smallest) Q1: >1% increase; (smallest) Q2: 1% 
(increase) to -6.5% (decrease); Q3: -6.5% to -13.7%; q4: -13.7% to -20%;  (largest 
decrease)Q5: <-20% decrease. p-value represents overall between group differences. 
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P=0.708 
 
 
 Figure 6: Adjusted survival plot for those patients with, and without an SBP-
reduction.  Adjusted for relevant baseline and in-hospital variables (listed in text). 
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Titration of Medications and measures of diuresis/decongestion 
Guideline directed medical therapies (GDMTs) did not result in higher incidence of WRF 
or compromise DE Table 4. Analysis compared patients continuing or increasing 
(including a new start on the medication) the dosage of their medications versus those 
who decreased, stopped, or never took the medications.  
ACE-I and/or ARBs: 
The dosage of ACE-I or ARBs was continued or increased in 71% (n=466) of patients. 
7.2% (n=47) of the study population had their ACE-I or ARB stopped anytime during 
admission. ACE-Is and/or ARBs did not increase the rates of WRF during hospitalization 
(OR: 0.90, 95% CI: 0.7-1.4, p=0.903) or at discharge (0.82, 95% CI: 0.5-1.3, p=0.395).  
However, ACE-Is or ARB use was strongly associated with high DE in both unadjusted 
(OR: 2.7, 95% CI: 1.9-3.8, p<0.0001) and adjusting for relevant baseline variables such 
as age, sex, hematocrit, hemoglobin, BNP, creatinine, and sodium, eGFR, ejection 
fraction, hypertension, diabetes, baseline ace-inhibitor or ARB, beta-blocker, thiazides, 
and hydralazine usage (OR: 1.99, 95% CI: 1.3-3.1, p=0.002).  
Beta-Blockers: 
A vast majority (88%, no=577) of the study population had their beta-blocker 
dosage continued at the same dosage or increased. Beta-blocker use in this group was 
associated with a reduced risk for WRF (OR: 0.6, 95% CI: 0.4-0.99, p=0.045) anytime 
during hospitalization and no increase in risk for WRF at the time of discharge (OR:1.64 
95% CI: 0.8-3.4, p=0.182). Diuretic efficiency was not affected by beta-blocker use 
(unadjusted OR for high DE: 1.41, 95% CI: 0.9-2.2, p=0.158). 
	   26	  
Table 4: Associations between medication variables and outcomes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACE-I, ARBs, and Beta Blockers were classified as patients with a new start, continuation, or increase in dosage during 
hospitalization. Sprionolactone represents all patients taking spironolactone without stopping during hospitalization. 2/3 
present indicates the patient was taking 2 of the 3 GDMT variables (ACE-I/ARB, BB, spironolactone). WRF=worsening of 
renal function. High DE=above median diuretic efficiency. Data is listed as odds ratio and 95% CI. 
 
 
 
 
 
 
Medication Variable: n SBP-reduction p Any WRF P WRF discharge P High DE P Adj. High DE p 
ACE and/or ARB 466 1.74 (1.2-2.4) 0.002* 0.90 (0.7-1.4) 0.903 0.82 (0.5-1.3) 0.395 2.7 (1.9-3.8) <0.001* 1.99 (1.3-3.1) 0.002* 
Beta Blocker 577 1.26 (0.8-2.0) 0.341 0.62 (0.4-0.99) 0.045* 1.64 (0.8-3.4) 0.182 1.41 (0.9-2.2) 0.158 1.3 (0.7-2.2) 0.365 
Spironolactone  148 0.98 (0.7-1.4) 0.925 0.90 (0.6-1.3) 0.602 0.74 (0.4-1.2) 0.269 1.1 (0.8-1.6) 0.561 1.01 (0.6-1.7) 0.986 
ACE/ARB+BB 417 1.65 (1.2-2.3) 0.002* 0.88 (0.6-1.2) 0.437 0.97 (0.6-1.5) 0.897 2.48 (1.8-3.4) <0.001* 1.76 (1.2-2.6) 0.005* 
ACE/ARB+BB+spiro 106 1.2 (0.8-1.9) 0.338 0.86 (0.6-1.3) 0.504 0.74 (0.4-1.3) 0.322 1.38 (0.9-2.1) 0.134 1.16 (0.7-1.9) 0.567 
2/3 present 452 1.56 (1.1-2.2) 0.009* 0.81 (0.6-1.1) 0.23 0.98 (0.6-1.5) 0.934 2.34 (1.7-3.3) <0.001* 1.59 (1.1-2.4) 0.025* 
Vasodilator given 286 1.13 (0.8-1.5) 0.431 1.28 (0.9-1.8) 0.131 1.25 (0.8-1.9) 0.288 0.75 (0.5-1.0) 0.064 0.73 (0.5-1.1) 0.122 
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Mineralocorticoid Receptor Antagonists: 
Spironolactone was compared between patients newly started or continuing (22%, 
n=148) versus those who either did not receive the medication or it was discontinued 
during hospitalization. Spironolactone was not associated with SBP-reduction (OR: 0.98, 
95% CI: 0.7-1.4, p=0.925) and similarly was not associated with WRF or high diuretic 
efficiency. 
GDMT combinations: 
Continuing and/or increasing the dosages ACE inhibitors/ARBs and beta-blockers 
occurred in 63% (n=417) of the study population. This medication combination 
associated with SBP-reduction (OR: 1.56, 95% CI: 1.1-2.2, p=0.009) without WRF (OR 
for developing WRF anytime during hospitalization: 0.88 95% CI: 0.6-1.2, p=0.437).  
Patients taking both of these medications were more likely to have high DE even when 
adjusting for relevant age, sex, hematocrit, hemoglobin, BNP, creatinine, and sodium, 
eGFR, ejection fraction, hypertension, diabetes, ace-inhibitor or ARB, beta-blocker, 
thiazides, and hydralazine usage (adjusted OR for high DE: 1.76, 95% CI: 1.2-2.6, 
p=0.005).  Similarly, a majority of the population (69%, n=452) took any 2 of the 3 
GDMTs. These patients had higher rates of SBP-reduction  (OR: 1.56, 95% CI: 1.1-2.2, 
p=0.009) and high DE (adjusted OR for High DE: 1.6, 95% CI:1.1-2.4, p=0.023) without 
a significant change in WRF (OR: 0.81, 95% CI: 0.6-1.1, p=0.23). Lastly, 16% (n=106) 
of patients were given continued or increased dosage of all three GDMTs. These patients 
interestingly did not have any change in their likelihood for SBP-reduction, WRF, or high 
DE (Table 4). 
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P=0.124 
 
 
Figure 8: Adjusted survival plot stratified by patients receiving 2 of 3 GDMT versus 
those not taking. Adjusted for relevant baseline and in-hospital variables (listed in 
text). 2 of 3 GDMT defined as same or increased dosage of any two of these: ACE-Is, 
beta blockers, and/or spironolactone. 
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GDMT and Mortality: 
 No individual medication or combination of GDMT was associated with higher 
mortality in both unadjusted and adjusted models. The extent to which these medications 
afforded a survival benefit varied, and is summarized in Table 5 and Figure 8.  
 
 
 
 
Table 5: GDMT and associations with mortality 
 Univariate Multivariate 
 HR (95%CI) p HR (95%CI) p 
ACE-I/ARB 0.59 (0.5-0.7) <0.0001 0.74 (0.5-1.0) 0.08 
Beta blocker 0.73 (0.54-0.99) 0.046 0.75 (0.53-1.1) 0.119 
Spironolactone 1.01 (0.8-1.3) 0.912 0.75 (0.4-1.3) 0.327 
SBP-reduction 0.79 (0.6-0.97) 0.026 1.05 (0.8-1.4) 0.708 
 
Hazard ratios for medication variables and SBP-reduction. SBP-reduction=>9.9% 
decrease in SBP. CE-I, ARBs, and Beta Blockers were classified as patients with a 
new start, continuation, or increase in dosage during hospitalization. Sprionolactone 
represents all patients taking spironolactone without stopping during 
hospitalization. 
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Discussion 
The present study demonstrates that a reduction in SBP was associated with 
deteriorations in renal function without compromising diuresis and decongestion.  SBP 
decreased in the majority of patients during hospitalization, and for those with a reduction 
in SBP greater than the median, the risk for WRF doubled. Nonetheless, there was no 
reduction in a wide array of metrics of decongestion including diuretic efficiency and 
hemoconcentration. Furthermore, patients starting, continuing, or increasing dosages of 
GDMT were more likely to have a reduction in blood pressure, an overall improvement 
in diuretic efficiency, and better prognosis.  
The link between reductions in SBP and WRF is becoming an accepted principle 
in cardiorenal pathology.40-42 Several physiologic mechanisms exist to explain the 
increased rates of WRF with SBP-reduction. The intricate autoregulation of glomerular 
blood flow by the kidney serves to maintain GFR over a wide range of blood-pressures.61 
However, the physiologic environment of congestive heart failure and ADHF therapy 
often disrupt this intricate balance, leading to deterioration in GFR. Longstanding 
medical comorbities such as diabetes and hypertension in addition to blood-pressure 
medications and diuretics can compromise renal autoregulation.50-52 The end result being 
that the kidney cannot appropriately respond to a decrease in blood pressure, leading to a 
decrease in GFR. Undoubtedly the high incidence of all of these factors in the study 
cohort led to the coupling of SBP-reduction and WRF seen in our analysis. Further 
highlighting the importance of these physiologic processes was the finding that patients 
with a higher admission SBP were more likely to develop WRF with SBP-reduction 
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while patients with lower admission SBP had similar rates of WRF, regardless of SBP-
reduction.  
Beyond the direct effect on GFR, little is known about the consequences of 
reducing SBP on treatment efficacy. As long as diuretic therapy remains the mainstay of 
decongestion in ADHF, the kidney will serve as the conduit for volume removal and as 
such any factors that affect kidney function could in theory compromise diuretic therapy. 
However, the results of our study suggest that SBP-reduction minimally effects diuretic 
efficiency during hospitalization. Diuretic efficiency was used to define treatment success 
because it has been proven to be an indicator of how effective the diuresis is during 
hospitalization and has prognostic significance.59 To ensure that study participants were 
not just diuresing well, but returning to a euvolemic state, rates of hemoconcentration 
were examined. Hemoconcentration can be used as a marker for decongestion, the 
primary treatment goal in ADHF, and is associated with better survival.62 As such, SBP-
reduction did not hinder the important goal of aggressive and complete decongestion.  
SBP-reduction was not linked to worse outcomes in our analysis. This result 
builds upon recent evidence demonstrating that WRF associated with SBP-reduction was 
not associated with worse outcomes.42 Several new concepts in ADHF research exist to 
help explain our findings in regards to prognosis. Firstly, the etiology of WRF is more 
relevant in determining prognosis than WRF taken alone. Therefore, the mechanisms by 
which SBP-reduction results in WRF may play less of a pathologic role in the 
progression of heart failure then other processes such as venous congestion or high 
dosages of loop-diuretics. Another important consideration for the low prognostic 
significance of SBP-reduction is the minor effect SBP-reduction had on therapy. It did 
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not impede one of the primary determinants of disease progression and survival, thorough 
decongestion.   
Another finding of this study was that starting, continuing, or increasing the dose 
of guideline medications was possible without impeding decongestion. GDMT use in this 
manner led to higher rates of SBP-reduction, which was to be expected considering these 
are antihypertensive medications. The controlled environment of hospitalization provides 
a perfect opportunity to optimize dosages. Consequently, it is encouraging that in this 
analysis all combinations of GDMT did not at any time reduce diuretic efficiency or 
survival.  
One unexpected result was the lack of association between continuing and/or 
increasing GDMT, especially ACE-I and ARBs, with WRF. While this result was not 
anticipated, other ADHF studies also noted a lack of association between ACE-I/ARBs 
and WRF during hospitalization.63,64 One explanation could be that an ADHF 
hospitalization presents a unique environment due to venous congestion, and subsequent 
aggressive diuretic therapy, altering renal autoregulation and increasing neurohormonal 
activation. In this context, the effect of ACE-Is and ARBs impart on GFR may be 
masked, or the effect could in some ways be protective by tempering the renal 
compensatory mechanisms in response to diuretic therapy.65 From a clinical practice 
standpoint, it was notable that any combination of GDMT (ACE-I/ARB, beta-blockers, 
spironolactone) did not reduce DE in our analysis. ACE-I/ARBs, alone or in combination 
with beta-blockers, were associated with high DE.  Higher DE with ACE-I/ARB use 
likely represents the direct effect of the drug lessening the hemodynamic and tubular 
changes in response to loop-diuretic therapy. Notably, a study by Chen et. Al. 
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demonstrated that furosemide-induced diuresis was substantially enhanced by the 
addition of losartan.66 Neurohormonal activation, which ACE-Is and ARBs partially 
block, play an important role in blunting the response to loop-diuretics by increasing the 
sodium avidity of the kidney. Reducing the tubular compensation and neurohormonal 
activation, which has repeatedly associated with worse outcomes, may be of greater 
importance to some extent than maintaining the autoregulation of glomerular blood flow 
and GFR. Just as increases of WRF secondary to a reduction in SBP result in a better 
prognosis, WRF associated with ACE-I use affords better outcomes than spontaneously 
occurring WRF.67  
 Taken as a whole, this investigation found that the society guideline 
recommended goals of aggressive decongestion and initiation and optimizing of medical 
therapy were compatible. SBP-reduction, a common result of both of these goals, did not 
affect treatment success or survival. Relatedly, the survival benefits afforded by GDMT 
were true in this cohort and did not come at the cost of DE or WRF. Current guidelines 
recommend the aforementioned goals to increase survival, but lack details on how best to 
consolidate therapies.23,24,53 Our analysis suggests this is generally possible, but more 
study is needed to understand the specifics. Further research will strengthen the fund of 
knowledge and, in turn, improve the detail of guideline recommendations and clinical 
decision-making. 
Limitations: 
 Given the post-hoc retrospective nature of this analysis, uncontrolled confounding 
cannot be excluded. SBP values for admission were the average of the first three values 
in the patient record, and these values came both from the emergency department and 
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patient room after admission. Therefore it is possible that some therapy (diuretics, blood-
pressure medications, inotropes, etc..) were administered between the first and third 
reading and could have influenced the final blood pressure values. The direct effect that 
day-to-day changes in SBP may have on diuresis cannot be assessed, as daily blood 
pressures and fluid output were not recorded in the database on a daily basis. Conclusions 
in this study were drawn over an entire hospitalization, and therefore specific changes in 
clinical values, or changes in therapy in response, may confound the data in a way that 
cannot be accounted for. Relatedly, only starting and stopping doses over the course of 
hospitalization for GDMT medications were used for analysis. Daily changes to the 
dosages of medications, the reason for these changes, and the effect these changes had on 
blood pressure, renal function, and diuretic efficiency, which could be used to guide 
therapy, were not part of this study. Relatedly, tailoring of the therapy could have altered 
the outcomes over the course of hospitalization. As a result of these limitations these 
findings should be regarded as hypothesis generating for future prospective studies.  
Conclusion: 
 SBP-reduction is associated with WRF but does not limit decongestion in ADHF. 
Continuing or increasing guideline direct medical therapy did not alter rates of WRF or 
diuretic success. 
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